These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 1332581

  • 1. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [Abstract] [Full Text] [Related]

  • 2. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 3. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA, Kauppinen R, Eskelinen M, Partanen K, Pikkarainen P, Alhava E.
    Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
    [Abstract] [Full Text] [Related]

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I.
    Anticancer Res; 1993 Mar; 13(5C):1883-7. PubMed ID: 8267397
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Mar; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [Abstract] [Full Text] [Related]

  • 9. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992 May; 12(6B):2309-14. PubMed ID: 1295478
    [Abstract] [Full Text] [Related]

  • 10. Differential diagnosis between benign and malignant biliary tract obstruction: discriminative usefulness of some clinical and laboratory data.
    Giusti G, Piccinino F, Sagnelli E, Pasquale G.
    Acta Hepatogastroenterol (Stuttg); 1975 Dec; 22(6):374-9. PubMed ID: 1211064
    [Abstract] [Full Text] [Related]

  • 11. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G, Manabe T, Watanabe Y, Endo K, Kudo H, Suzuki T, Tobe T.
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW, Tong KJ, Tam TN, Lee SD.
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [Abstract] [Full Text] [Related]

  • 14. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV, Edwards R, Ho S, Lau WY, Glazer G.
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [Abstract] [Full Text] [Related]

  • 15. Tumour markers in pancreatic cancer.
    Haglund C, Kuusela P, Roberts PJ.
    Ann Chir Gynaecol; 1989 Aug; 78(1):41-53. PubMed ID: 2667448
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, Tarvainen R, Nuutinen P, Pääkkönen M, Alhava E.
    Anticancer Res; 1994 Aug; 14(3B):1427-32. PubMed ID: 8067718
    [Abstract] [Full Text] [Related]

  • 17. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R, Meyer-Wyss B, Herzog U, Tondelli P.
    Schweiz Med Wochenschr; 1999 Jan 23; 129(3):77-9. PubMed ID: 10065510
    [Abstract] [Full Text] [Related]

  • 18. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
    Taylor OM, Cooper EH, Benson EA, McMahon MJ.
    Eur J Surg Oncol; 1992 Oct 23; 18(5):508-13. PubMed ID: 1426303
    [Abstract] [Full Text] [Related]

  • 19. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M, Hyöty H, Aaran RK, Airo I, Nordback I.
    Eur J Surg; 1992 Mar 23; 158(3):173-9. PubMed ID: 1356458
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J, Genolla J, Ruibal A.
    Am J Gastroenterol; 1993 Mar 23; 88(3):409-12. PubMed ID: 8438849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.